Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Triple Negative Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma, Cutaneous Malignant 1Head and Neck Neoplasms 1GastroEsophageal Cancer 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1CLDN18.2 Positive 1Anal Cancer Metastatic 1Adenocarcinoma 1

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × 30 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡